Eleni Aklillu

Publikationer
Forskningsbidrag
CV
Populärvetenskap och samverkan

Artiklar

Article: DRUG SAFETY. 2024;47(12):1193-1202
Short-Term Training, a Useful Approach for Sustainable Pharmacovigilance Knowledge Development in Tanzania, Kenya, Ethiopia and Rwanda
van Puijenbroek E; Barry A; Khaemba C; Ntirenganya L; Gebreyesus TD; Fimbo A; Minzi O; Makonnen E; Oluka M; Guantai A; Aklillu E
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2024;90(11):2823-2836
CYP2B6 and ABCB1 genotypes predict methadone plasma exposure among patients on maintenance therapy against opioid addictions in Tanzania
Mugusi S; Mnkugwe RH; Sanga AA; Salahuddin A; Barclay V; Shayo G; Dahl M-L; Aklillu E
Article: BMC INFECTIOUS DISEASES. 2024;24(1):901
The safety of a dolutegravir (DTG)-based antiretroviral treatment (ART) regimen for pregnancy and birth outcomes in Ethiopia: evidence from multicenter cohort study
Gedefaw A; Tadesse BT; Berhan Y; Makonnen E; Vella S; Aklillu E
Article: BMC PHARMACOLOGY AND TOXICOLOGY. 2024;25(1):38
Pharmacokinetics of piperaquine and its association with intermittent malaria preventive therapy outcomes during pregnancy
Mlugu EM; Minzi OMS; Johansson M; Kamuhabwa AAR; Aklillu E
Article: INFECTIOUS DISEASES OF POVERTY. 2024;13(1):44
Efficacy of ivermectin and albendazole combination in suppressing transmission of lymphatic filariasis following mass administration in Tanzania: a prospective cohort study
Fimbo AM; Mnkugwe RH; Mlugu EM; Kunambi PP; Malishee A; Minzi OMS; Kamuhabwa AAR; Aklillu E
Article: SCIENTIFIC REPORTS. 2024;14(1):11730
CYP2C19 and CYP2J2 genotypes predict praziquantel plasma exposure among Ethiopian school-aged children
Gebreyesus TD; Makonnen E; Telele NF; Barry A; Mnkugwe RH; Gerba H; Dahl M-L; Aklillu E
Article: INFECTIOUS DISEASES. 2024;56(4):308-319
Variability in plasma rifampicin concentrations and role of SLCO1B1, ABCB1, AADAC2 and CES2 genotypes in Ethiopian patients with tuberculosis
Sileshi T; Makonnen E; Telele NF; Barclay V; Zumla A; Aklillu E
Article: INFECTIOUS DISEASES OF POVERTY. 2024;13(1):8
Reduced efficacy of single-dose albendazole against Ascaris lumbricoides, and Trichuris trichiura, and high reinfection rate after cure among school children in southern Ethiopia: a prospective cohort study
Gebreyesus TD; Makonnen E; Tadele T; Mekete K; Gashaw H; Gerba H; Aklillu E
Article: TROPICAL MEDICINE AND HEALTH. 2023;51(1):72
Efficacy and safety of praziquantel treatment against Schistosoma mansoni infection among pre-school age children in southern Ethiopia
Tadele T; Astatkie A; Tadesse BT; Makonnen E; Aklillu E; Abay SM
Article: CPT: PHARMACOMETRICS AND SYSTEMS PHARMACOLOGY. 2023;12(12):1884-1896
Population pharmacokinetics of ivermectin after mass drug administration in lymphatic filariasis endemic communities of Tanzania
Fimbo AM; Mlugu EM; Kitabi EN; Kulwa GS; Iwodyah MA; Mnkugwe RH; Kunambi PP; Malishee A; Kamuhabwa AAR; Minzi OM; Aklillu E
Article: DRUG SAFETY. 2023;46(10):961-974
Comparative Safety Surveillance of Triple (IDA) Versus Dual Therapy (DA) in Mass Drug Administration for Elimination of Lymphatic Filariasis in Kenya: A Cohort Event Monitoring Study
Khaemba C; Barry A; Omondi WP; Kirui E; Oluka M; Parthasarathi G; Njenga SM; Guantai A; Aklillu E
Article: PATHOGENS. 2023;12(9):1170
Efficacy of Single-Dose Praziquantel for the Treatment of Schistosoma mansoni Infections among School Children in Rwanda
Kabatende J; Ntirenganya L; Mugisha M; Barry A; Ruberanziza E; Bienvenu E; Bergman U; Aklillu E
Article: SCIENTIFIC REPORTS. 2023;13(1):11438
Correlation of N-acetyltransferase 2 genotype and acetylation status with plasma isoniazid concentration and its metabolic ratio in ethiopian tuberculosis patients
Sileshi T; Telele NF; Burkley V; Makonnen E; Aklillu E
Article: PATHOGENS. 2023;12(7):858
Prevalence and Determinants of Schistosoma mansoni Infection among Pre-School Age Children in Southern Ethiopia
Tadele T; Astatkie A; Abay SM; Tadesse BT; Makonnen E; Aklillu E
Article: CPT: PHARMACOMETRICS AND SYSTEMS PHARMACOLOGY. 2023;12(6):783-794
Genetic and non-genetic factors influencing efavirenz population pharmacokinetics among human immunodeficiency virus-1-infected children in Ethiopia
Chala A; Kitabi EN; Ahmed JH; Tadesse BT; Chaka TE; Makonnen E; Aklillu E
Article: SCIENTIFIC REPORTS. 2023;13(1):1446
Effect of pharmacogenetic variations on praziquantel plasma concentration and safety outcomes among school children in Rwanda
Barry A; Kabatende J; Telele NF; Mnkugwe RH; Mugisha M; Ntirenganya L; Bienvenu E; Aklillu E
Article: PHARMACEUTICALS. 2023;16(2):139
Efficacy of Single-Dose Albendazole for the Treatment of Soil-Transmitted Helminthic Infections among School Children in Rwanda-A Prospective Cohort Study
Kabatende J; Barry A; Mugisha M; Ntirenganya L; Bergman U; Bienvenu E; Aklillu E
Article: ETHIOPIAN JOURNAL OF HEALTH DEVELOPMENT. 2023;37(1)
Methicillin Resistant Staphylococcus aureus contamination of Health care worker gowns and Uniforms: A cross-sectional Study from the biggest teaching hospital in Ethiopia
Desta K; Aklillu E; Gebrehiwot Y; Enquoselassie F; Cantillon D; Al-Hassan L; Price JR; Newport MJ; Davey G; Woldeamanuel Y
Article: FRONTIERS IN PHARMACOLOGY. 2023;14:968106
Efficacy and safety of praziquantel preventive chemotherapy in Schistosoma mansoni infected school children in Southern Ethiopia: A prospective cohort study
Gebreyesus TD; Makonnen E; Tadele T; Mekete K; Gashaw H; Gerba H; Aklillu E
Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022;23(23):15168
Pregnancy Increases CYP3A Enzymes Activity as Measured by the 4β-Hydroxycholesterol/Cholesterol Ratio
Mlugu EM; Minzi OM; Kamuhabwa AAR; Diczfalusy U; Aklillu E
Article: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2022;124:S69-S74
Blue Skies research is essential for ending the Tuberculosis pandemic and advancing a personalized medicine approach for holistic management of Respiratory Tract infections
Ntoumi F; Petersen E; Mwaba P; Aklillu E; Mfinanga S; Yeboah-Manu D; Maeurer M; Zumla A
Article: JOURNAL OF CLINICAL MEDICINE. 2022;11(21):6300
Safety Surveillance of Mass Praziquantel and Albendazole Co-Administration in School Children from Southern Ethiopia: An Active Cohort Event Monitoring
Gebreyesus TD; Makonnen E; Tadele T; Gashaw H; Degefe W; Gerba H; Tadesse BT; Gurumurthy P; Aklillu E
Article: DRUG SAFETY. 2022;45(8):909-922
Safety of Praziquantel and Albendazole Coadministration for the Control and Elimination of Schistosomiasis and Soil-Transmitted Helminths Among Children in Rwanda: An Active Surveillance Study
Kabatende J; Barry A; Mugisha M; Ntirenganya L; Bergman U; Bienvenu E; Aklillu E
Article: JOURNAL OF PERSONALIZED MEDICINE. 2022;12(7):1087
CYP3A and CYP2B6 Genotype Predicts Glucose Metabolism Disorder among HIV Patients on Long-Term Efavirenz-Based ART: A Case-Control Study
Tadesse WT; Mlugu EM; Shibeshi W; Degu WA; Engidawork E; Aklillu E
Article: SCIENTIFIC REPORTS. 2022;12(1):9698
Constitutive androstane receptor and pregnane X receptor genotype influence efavirenz plasma concentration and CYP2B6 enzyme activity
Petros Z; Habtewold A; Makonnen E; Aklillu E
Article: PHARMACEUTICALS. 2022;15(5):594
Safety and Tolerability of Ivermectin and Albendazole Mass Drug Administration in Lymphatic Filariasis Endemic Communities of Tanzania: A Cohort Event Monitoring Study
Fimbo AM; Minzi OM; Mmbando BP; Gurumurthy P; Kamuhabwa AAR; Aklillu E
Article: INFECTION AND DRUG RESISTANCE. 2022;15:3135-3147
High Levels of Methicillin-Resistant Staphylococcus aureus Carriage Among Healthcare Workers at a Teaching Hospital in Addis Ababa Ethiopia: First Evidence Using mecA Detection
Desta K; Aklillu E; Gebrehiwot Y; Enquselassie F; Cantillon D; Al-Hassan L; Price JR; Newport MJ; Davey G; Woldeamanuel Y
Article: INFECTION AND DRUG RESISTANCE. 2022;15:6839-6852
Population Pharmacokinetics of Levofloxacin and Moxifloxacin, and the Probability of Target Attainment in Ethiopian Patients with Multidrug-Resistant Tuberculosis
Sidamo T; Rao PS; Aklillu E; Shibeshi W; Park Y; Cho Y-S; Shin J-G; Heysell SK; Mpagama SG; Engidawork E
Article: PLOS ONE. 2022;17(1):e0262604
Prevalence and predictors of glucose metabolism disorders among People Living with HIV on combination antiretroviral therapy
Tadesse WT; Adankie BT; Shibeshi W; Amogne W; Aklillu E; Engidawork E
Article: JOURNAL OF PERSONALIZED MEDICINE. 2021;11(12):1303
Predictors of Efavirenz Plasma Exposure, Auto-Induction Profile, and Effect of Pharmacogenetic Variations among HIV-Infected Children in Ethiopia: A Prospective Cohort Study
Chala A; Tadesse BT; Chaka TE; Mukonzo J; Kitabi EN; Tadesse S; Pohanka A; Makonnen E; Aklillu E
Article: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2021;113(Suppl 1):S7-S12
Global Tuberculosis Report 2020-Reflections on the Global TB burden, treatment and prevention efforts
Chakaya J; Khan M; Ntoumi F; Aklillu E; Fatima R; Mwaba P; Kapata N; Mfinanga S; Hasnain SE; Katoto PDMC; Bulabula ANH; Sam-Agudu NA; Nachega JB; Tiberi S; McHugh TD; Abubakar I; Zumla A
Article: CLINICAL PHARMACOLOGY AND THERAPEUTICS. 2021;110(6):1478-1489
Effectiveness of Intermittent Preventive Treatment With Dihydroartemisinin-Piperaqunine Against Malaria in Pregnancy in Tanzania: A Randomized Controlled Trial
Mlugu EM; Minzi O; Kamuhabwa AAR; Aklillu E
Article: SCIENTIFIC REPORTS. 2021;11(1):17955
Optimal single sampling time-point for monitoring of praziquantel exposure in children
Mnkugwe RH; Ngaimisi Kitabi E; Kinung'hi S; Kamuhabwa AAR; Minzi OM; Aklillu E
Article: BRITISH JOURNAL OF PHARMACOLOGY. 2021;178(16):3294-3308
Early or deferred initiation of efavirenz during rifampicin-based TB therapy has no significant effect on CYP3A induction in TB-HIV infected patients
Aklillu E; Zumla A; Habtewold A; Amogne W; Makonnen E; Yimer G; Burhenne J; Diczfalusy U
Article: PHARMACEUTICALS. 2021;14(5):400
Effect of Dihydroartemisinin-Piperaquine on the Pharmacokinetics of Praziquantel for Treatment of Schistosoma mansoni Infection
Minzi OM; Mnkugwe RH; Ngaimisi E; Kinung'hi S; Hansson A; Pohanka A; Kamuhabwa A; Aklillu E
Article: PHARMACEUTICALS. 2021;14(3):264
Safety and Tolerability of Mass Diethylcarbamazine and Albendazole Administration for the Elimination of Lymphatic Filariasis in Kenya: An Active Surveillance Study
Khaemba C; Barry A; Omondi WP; Bota K; Matendechero S; Wandera C; Siyoi F; Kirui E; Oluka M; Nambwa P; Gurumurthy P; Njenga SM; Guantai A; Aklillu E
Article: INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH. 2021;18(4):1941
Comparative Assessment of the Pharmacovigilance Systems within the Neglected Tropical Diseases Programs in East Africa-Ethiopia, Kenya, Rwanda, and Tanzania
Barry A; Olsson S; Khaemba C; Kabatende J; Dires T; Fimbo A; Minzi O; Bienvenu E; Makonnen E; Kamuhabwa A; Oluka M; Guantai A; van Puijenbroek E; Bergman U; Nkayamba A; Mugisha M; Gurumurthy P; Aklillu E
Article: BMC MEDICAL EDUCATION. 2021;21(1):36
Understanding the key processes of excellence as a prerequisite to establishing academic centres of excellence in Africa
Fekadu A; Oppenheim C; Manyazewal T; Nislow C; Woldeamanuel Y; Hailu A; Belete A; Wondimagegn D; Hanlon C; Gebremariam T; Collins A; Larson CJ; Gebreyes W; Aklilu E; Muula AS; Mugus S; Caffery C; Giday M; Yimer G; Davey G; Medhin G; Makonnen E
Article: FRONTIERS IN PHARMACOLOGY. 2021;12:712084
Effect of Pharmacogenetics Variations on Praziquantel Plasma Concentrations and Schistosomiasis Treatment Outcomes Among Infected School-Aged Children in Tanzania
Mnkugwe RH; Minzi O; Kinung'hi S; Kamuhabwa A; Aklillu E
Article: INFECTION AND DRUG RESISTANCE. 2021;14:5473-5489
Explorative Analysis of Treatment Outcomes of Levofloxacin- and Moxifloxacin-Based Regimens and Outcome Predictors in Ethiopian MDR-TB Patients: A Prospective Observational Cohort Study
Sidamo T; Shibeshi W; Yimer G; Aklillu E; Engidawork E
Article: CLINICAL PHARMACOLOGY: ADVANCES AND APPLICATIONS. 2021;13:1-12
The Impact of First-Line Anti-Tubercular Drugs' Pharmacokinetics on Treatment Outcome: A Systematic Review
Sileshi T; Tadesse E; Makonnen E; Aklillu E
Article: PEDIATRIC INFECTIOUS DISEASE JOURNAL. 2021;40(1):60-65
Predictors of Virologic Failure Among a Cohort of HIV-infected Children in Southern Ethiopia
Tadesse BT; Foster BA; Latour E; Lim JY; Jerene D; Ruff A; Aklillu E
Article: PATHOGENS. 2020;9(12):1076
Prevalence, Intensity, and Correlates of Soil-Transmitted Helminth Infections among School Children after a Decade of Preventive Chemotherapy in Western Rwanda
Kabatende J; Mugisha M; Ntirenganya L; Barry A; Ruberanziza E; Mbonigaba JB; Bergman U; Bienvenu E; Aklillu E
Article: PATHOGENS. 2020;9(11):E920-920
Prevalence, Intensity, and Correlates of Schistosomiasis and Soil-Transmitted Helminth Infections after Five Rounds of Preventive Chemotherapy among School Children in Southern Ethiopia
Gebreyesus TD; Tadele T; Mekete K; Barry A; Gashaw H; Degefe W; Tadesse BT; Gerba H; Gurumurthy P; Makonnen E; Aklillu E
Article: PLOS NEGLECTED TROPICAL DISEASES. 2020;14(9):e0008619
Efficacy and safety of praziquantel and dihydroartemisinin piperaquine combination for treatment and control of intestinal schistosomiasis: A randomized, non-inferiority clinical trial
Mnkugwe RH; Minzi O; Kinung'hi S; Kamuhabwa A; Aklillu E
Article: JOURNAL OF CLINICAL MEDICINE. 2020;9(5):E1550-1550
Prevalence and Correlates of Lymphatic Filariasis Infection and Its Morbidity Following Mass Ivermectin and Albendazole Administration in Mkinga District, North-Eastern Tanzania
Fimbo AM; Minzi OMS; Mmbando BP; Barry A; Nkayamba AF; Mwamwitwa KW; Malishee A; Seth MD; Makunde WH; Gurumurthy P; Lusingu JPA; Kamuhabwa AAR; Aklillu E
Article: INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH. 2020;17(9):E3123-3123
Prevalence and Correlates of Asymptomatic Malaria and Anemia on First Antenatal Care Visit among Pregnant Women in Southeast, Tanzania
Mlugu EM; Minzi O; Kamuhabwa AAR; Aklillu E
Article: MALARIA JOURNAL. 2020;19(1):160
Effect of sulfadoxine-pyrimethamine doses for prevention of malaria during pregnancy in hypoendemic area in Tanzania
Mikomangwa WP; Minzi O; Mutagonda R; Baraka V; Mlugu EM; Aklillu E; Kamuhabwa AAR
Article: DRUG SAFETY. 2020;43(4):339-350
Comparative Assessment of the National Pharmacovigilance Systems in East Africa: Ethiopia, Kenya, Rwanda and Tanzania
Barry A; Olsson S; Minzi O; Bienvenu E; Makonnen E; Kamuhabwa A; Oluka M; Guantai A; Bergman U; van Puijenbroek E; Gurumurthy P; Aklillu E
Article: PATHOGENS. 2020;9(3):E207-207
Effectiveness of Sulfadoxine-Pyrimethamine for Intermittent Preventive Treatment of Malaria and Adverse Birth Outcomes in Pregnant Women
Mlugu EM; Minzi O; Asghar M; Farnert A; Kamuhabwa AAR; Aklillu E
Article: EXPERT REVIEW OF CARDIOVASCULAR THERAPY. 2020;18(3):165-173
Profiles of patients on warfarin anticoagulation therapy in a leading tertiary referral hospital in Kenya; findings and implications for Kenya
Nyamu DG; Guantai AN; Osanjo GO; Godman B; Aklillu E
Article: MALARIA JOURNAL. 2020;19(1):66
Usefulness of day 7 lumefantrine plasma concentration as a predictor of malaria treatment outcome in under-fives children treated with artemether-lumefantrine in Tanzania
Kilonzi M; Minzi O; Mutagonda R; Baraka V; Sasi P; Aklillu E; Kamuhabwa A
Article: TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE. 2020;114(2):107-114
Role of pharmacogenetics in rifampicin pharmacokinetics and the potential effect on TB-rifampicin sensitivity among Ugandan patients
Mukonzo JK; Kengo A; Kutesa B; Nanzigu S; Pohanka A; McHugh TD; Zumla A; Aklillu E
Article: WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY. 2020;21(1):29-52
Cigarette smoking and heavy coffee consumption affecting response to olanzapine: The role of genetic polymorphism
Djordjevic N; Radmanovic B; Cukic J; Baskic D; Djukic-Dejanovic S; Milovanovic D; Aklillu E
Article: FRONTIERS IN PHARMACOLOGY. 2020;11:406
Population Pharmacokinetic, Pharmacogenetic, and Pharmacodynamic Analysis of Cyclophosphamide in Ethiopian Breast Cancer Patients
Ahmed JH; Makonnen E; Bisaso RK; Mukonzo JK; Fotoohi A; Aseffa A; Howe R; Hassan M; Aklillu E
Article: FRONTIERS IN PHARMACOLOGY. 2020;11:26
Impact of Population and Pharmacogenetics Variations on Efavirenz Pharmacokinetics and Immunologic Outcomes During Anti-Tuberculosis Co-Therapy: A Parallel Prospective Cohort Study in Two Sub-Sahara African Populations
Mugusi S; Habtewold A; Ngaimisi E; Amogne W; Yimer G; Minzi O; Makonnen E; Sudfeld C; Burhenne J; Aklillu E
Article: PLOS ONE. 2020;15(2):e0228770
Prevalence and correlates of intestinal schistosomiasis infection among school-aged children in North-Western Tanzania
Mnkugwe RH; Minzi OS; Kinung'hi SM; Kamuhabwa AA; Aklillu E
Article: PATHOGENS. 2019;9(1):E28-28
Efficacy and Safety of Praziquantel for Treatment of Schistosoma mansoni Infection among School Children in Tanzania
Mnkugwe RH; Minzi OS; Kinung'hi SM; Kamuhabwa AA; Aklillu E
Article: DRUG METABOLISM AND DISPOSITION. 2019;47(12):1415-1424
Pregnancy and CYP3A5 Genotype Affect Day 7 Plasma Lumefantrine Concentrations
Mutagonda RF; Minzi OMS; Massawe SN; Asghar M; Farnert A; Kamuhabwa AAR; Aklillu E
Journal article: PHARMACOGENETICS AND GENOMICS. 2019;29(9):224
PharmGKB summary: very important pharmacogene information for CYP1A2 (vol 22, pg 73, 2012)
Thorn CF; Aklillu E; Klein TE; Altman RB
Article: PATHOGENS. 2019;8(4):E161-161
Rates and Correlates of Short Term Virologic Response among Treatment-Naive HIV-Infected Children Initiating Antiretroviral Therapy in Ethiopia: A Multi-Center Prospective Cohort Study
Tadesse BT; Chala A; Mukonzo J; Chaka TE; Tadesse S; Makonnen E; Brumme ZL; Brumme CJ; Aklillu E
Article: VIRUSES. 2019;11(9):E877-877
Prevalence and Correlates of Pre-Treatment HIV Drug Resistance among HIV-Infected Children in Ethiopia
Tadesse BT; Tsai O; Chala A; Chaka TE; Eromo T; Lapointe HR; Baraki B; Shahid A; Tadesse S; Makonnen E; Brumme ZL; Aklillu E; Brumme CJ
Article: CANCERS. 2019;11(9):E1353-1353
CYP2D6 Genotype Predicts Plasma Concentrations of Tamoxifen Metabolites in Ethiopian Breast Cancer Patients
Ahmed JH; Makonnen E; Fotoohi A; Aseffa A; Howe R; Aklillu E
Article: BMC PREGNANCY AND CHILDBIRTH. 2019;19(1):236
Adverse birth outcomes among mothers who received intermittent preventive treatment with Sulphadoxine-Pyrimethamine in the low malaria transmission region
Mikomangwa WP; Minzi OMS; Aklillu E; Kamuhabwa AAR
Article: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2019;83:98-101
Potential drug-drug interactions between antiretroviral therapy and treatment regimens for multi-drug resistant tuberculosis: Implications for HIV care of MDR-TB co-infected individuals
Mukonzo J; Aklillu E; Marconi V; Schinazi RF
Article: MALARIA JOURNAL. 2019;18(1):133
Comparison of malaria treatment outcome of generic and innovator's anti-malarial drugs containing artemether-lumefantrine combination in the management of uncomplicated malaria amongst Tanzanian children
Kilonzi M; Minzi O; Mutagonda R; Sasi P; Kamuhabwa A; Aklillu E
Article: JOURNAL OF CLINICAL MEDICINE. 2019;8(4):E430-430
HIV and cART-Associated Dyslipidemia Among HIV-Infected Children
Tadesse BT; Foster BA; Chala A; Chaka TE; Bizuayehu T; Ayalew F; Meskel GH; Tadesse S; Jerene D; Makonnen E; Aklillu E
Article: HIV MEDICINE. 2019;20(2):147-156
Hepatic and renal toxicity and associated factors among HIV-infected children on antiretroviral therapy: a prospective cohort study
Tadesse BT; Foster BA; Kabeta A; Ayalew F; Meskel GH; Jerene D; Makonnen E; Aklillu E
Article: NUTRIENTS. 2019;11(2):E289-289
Vitamin D Status and Association of VDR Genetic Polymorphism to Risk of Breast Cancer in Ethiopia
Ahmed JH; Makonnen E; Fotoohi A; Yimer G; Seifu D; Assefa M; Tigeneh W; Aseffa A; Howe R; Aklillu E
Article: AAS OPEN RESEARCH. 2019;2:19
African Pharmacogenomics Consortium: Consolidating pharmacogenomics knowledge, capacity development and translation in Africa: Consolidating pharmacogenomics knowledge, capacity development and translation in Africa.
Dandara C; Masimirembwa C; Haffani YZ; Ogutu B; Mabuka J; Aklillu E; Bolaji O; H3Africa
Article: FRONTIERS IN PHARMACOLOGY. 2019;10:481
CYP2J2*7 Genotype Predicts Risk of Chemotherapy-Induced Hematologic Toxicity and Reduced Relative Dose Intensity in Ethiopian Breast Cancer Patients
Ahmed JH; Makonnen E; Yimer G; Seifu D; Bekele A; Assefa M; Aseffa A; Howes R; Fotoohi A; Hassan M; Aklillu E
Journal article: 2018
Rifampicin-Efavirenz Drug Interactions and Cytochrome P450 3A (CYP3A) Enzyme Induction in Patients with Tuberculosis and HIV Co-Infection - A Prospective Cohort Study
Aklillu E; Zumla A; Habtewold A; Amogne W; Makonnen E; Yimer G; Nylé n H; Bertilsson L; Burhenne JUR; Diczfalusy U
Article: SCIENTIFIC REPORTS. 2018;8(1):16316
Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype
Kitabi EN; Minzi OMS; Mugusi S; Sasi P; Janabi M; Mugusi F; Bertilsson L; Burhenne J; Aklillu E
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2018;74(11):1405-1415
Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin
Mugusi S; Ngaimisi E; Janabi M; Mugusi F; Minzi O; Aris E; Bakari M; Bertilsson L; Burhenne J; Sandstrom E; Aklillu E
Article: SCIENTIFIC REPORTS. 2018;8(1):12726
Effects of Khat (Catha edulis) use on catalytic activities of major drug-metabolizing cytochrome P450 enzymes and implication of pharmacogenetic variations
Bedada W; de Andres F; Engidawork E; Hussein J; LLerena A; Aklillu E
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2018;74(7):903-911
N-Acetyltransferase-2 (NAT2) phenotype is influenced by genotype-environment interaction in Ethiopians
Aklillu E; Antonio Carrillo J; Makonnen E; Bertilsson L; Djordjevic N
Article: VIRUSES. 2018;10(2):E60-60
High Levels of Dual-Class Drug Resistance in HIV-Infected Children Failing First-Line Antiretroviral Therapy in Southern Ethiopia
Tadesse BT; Kinloch NN; Baraki B; Lapointe HR; Cobarrubias KD; Brockman MA; Brumme CJ; Foster BA; Jerene D; Makonnen E; Aklillu E; Brumme ZL
Journal article: PROCEEDINGS FOR ANNUAL MEETING OF THE JAPANESE PHARMACOLOGICAL SOCIETY. 2018;WCP2018(0):sy48-sy42
African Pharmacogenomics Research Consortium: Focus on HIV, Tuberculosis and Malaria treatment
Aklillu E
Article: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2017;61(8):e00207-e00217
Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients
Habtewold A; Aklillu E; Makonnen E; Yimer G; Bertilsson L; Burhenne J; Owen JS
Article: MALARIA JOURNAL. 2017;16(1):267
Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women
Mutagonda RF; Kamuhabwa AAR; Minzi OMS; Massawe SN; Asghar M; Homann MV; Farnert A; Aklillu E
Article: OMICS A JOURNAL OF INTEGRATIVE BIOLOGY. 2017;21(4):207-216
Genome-Wide Association and Replication Study of Hepatotoxicity Induced by Antiretrovirals Alone or with Concomitant Anti-Tuberculosis Drugs
Petros Z; Lee MTM; Takahashi A; Zhang Y; Yimer G; Habtewold A; Schuppe-Koistinen I; Mushiroda T; Makonnen E; Kubo M; Aklillu E
Journal article: BMJ GLOBAL HEALTH. 2017;2(Suppl 2):a39
CYP2B6 GENOTYPE BASED EFAVIRENZ DOSE RECOMMENDATIONS DURING RIFAMPICIN-BASED ANTITUBERCULOSIS CO-TREATMENT FOR A SUB-SAHARAN AFRICA POPULATION
Mukonzo J; Kuteesa R; Ogwal-Okeng J; Gustafsson LL; Owen J; Aklillu E
Journal article: BMJ GLOBAL HEALTH. 2017;2(Suppl 2):a11
PREVALENCE AND RISK FACTORS FOR EFAVIRENZ-BASED ANTIRETROVIRAL TREATMENT-ASSOCIATED SEVERE VITAMIN D DEFICIENCY: A PROSPECTIVE COHORT STUDY
Nylén H; Habtewold A; Makonnen E; Yimer G; Burhenne J; Diczfalusy U; Aklillu E
Journal article: BMJ GLOBAL HEALTH. 2017;2(Suppl 2):a1-a72
Abstracts of the Eighth EDCTP Forum, 6-9 November 2016.
Article: FRONTIERS IN PHARMACOLOGY. 2017;8:90
HLA-B*57 Allele Is Associated with Concomitant Anti-tuberculosis and Antiretroviral Drugs Induced Liver Toxicity in Ethiopians
Petros Z; Kishikawa J; Makonnen E; Yimer G; Habtewold A; Aklillu E
Article: LIVER INTERNATIONAL. 2017;37(1):132-140
Elevated levels of circulating CDH5 and FABP1 in association with human drug-induced liver injury
Mikus M; Drobin K; Gry M; Bachmann J; Lindberg J; Yimer G; Aklillu E; Makonnen E; Aderaye G; Roach J; Fier I; Kampf C; Goepfert J; Perazzo H; Poynard T; Stephens C; Andrade RJ; Isabel Lucena M; Arber N; Uhlen M; Watkins PB; Schwenk JM; Nilsson P; Schuppe-Koistinen I
Article: JOURNAL OF CLINICAL PHARMACOLOGY. 2016;56(12):1538-1549
Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients
Habtewold A; Aklillu E; Makonnen E; Amogne W; Yimer G; Aderaye G; Bertilsson L; Owen JS; Burhenne J
Article: BMC GENOMICS. 2016;17(1):755
Genome-wide association and replication study of anti-tuberculosis drugs-induced liver toxicity
Petros Z; Lee M-TM; Takahashi A; Zhang Y; Yimer G; Habtewold A; Amogne W; Aderaye G; Schuppe-Koistinen I; Mushiroda T; Makonnen E; Kubo M; Aklillu E
Article: OMICS A JOURNAL OF INTEGRATIVE BIOLOGY. 2016;20(9):538-545
SLCO1B1 Gene Variations Among Tanzanians, Ethiopians, and Europeans: Relevance for African and Worldwide Precision Medicine
Aklillu E; Habtewold A; Ngaimisi E; Yimer G; Mugusi S; Amogne W; Reuter T; Meid A; Hoffmann MM; Weiss J
Article: OMICS A JOURNAL OF INTEGRATIVE BIOLOGY. 2016;20(9):496-497
Conference Report: First Pharmacogenetics and Precision Medicine Conference in Africa (April 7-9, 2016, Cape Town, South Africa)
Dandara C; Suarez-Kurtz G; Aklillu E
Article: MEDICINE (UNITED KINGDOM). 2016;95(34):e4631
Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency: A prospective cohort study
Nylen H; Habtewold A; Makonnen E; Yimer G; Bertilsson L; Burhenne J; Diczfalusy U; Aklillu E
Article: MALARIA JOURNAL. 2016;15(1):278
Malaria prevalence, severity and treatment outcome in relation to day 7 lumefantrine plasma concentration in pregnant women
Mutagonda RF; Kamuhabwa AAR; Minzi OMS; Massawe SN; Maganda BA; Aklillu E
Article: PHARMACOGENOMICS. 2016;17(6):603-613
CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population
Mukonzo JK; Bisaso RK; Ogwal-Okeng J; Gustafsson LL; Owen JS; Aklillu E
Article: PHARMACOGENOMICS JOURNAL. 2016;16(1):88-95
CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients
Maganda BA; Minzi OMS; Ngaimisi E; Kamuhabwa AAR; Aklillu E
Article: PLOS ONE. 2016;11(8):e0161685
High Gastrointestinal Colonization Rate with Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in Hospitalized Patients: Emergence of Carbapenemase-Producing K. pneumoniae in Ethiopia
Desta K; Woldeamanuel Y; Azazh A; Mohammod H; Desalegn D; Shimelis D; Gulilat D; Lamisso B; Makonnen E; Worku A; Mannerqvist K; Struwe J; Aspevall O; Aklillu E
Article: PHARMACOLOGY RESEARCH & PERSPECTIVES. 2015;3(6):e00192
miRNA-27b levels are associated with CYP3A activity in vitro and in vivo.
Ekström L; Skilving I; Ovesjö M-L; Aklillu E; Nylén H; Rane A; Diczfalusy U; Björkhem-Bergman L
Article: JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY. 2015;35(6):694-699
The Psychostimulant Khat (Catha edulis) Inhibits CYP2D6 Enzyme Activity in Humans
Bedada W; de Andres F; Engidawork E; Pohanka A; Beck O; Bertilsson L; Llerena A; Aklillu E
Article: OMICS A JOURNAL OF INTEGRATIVE BIOLOGY. 2015;19(12):777-781
P450 (Cytochrome) Oxidoreductase Gene (POR) Common Variant (POR*28) Significantly Alters CYP2C9 Activity in Swedish, But Not in Korean Healthy Subjects
Hatta FHM; Aklillu E
Article: DRUG METABOLISM AND DISPOSITION. 2015;43(8):1226-1235
The CYP2C19 Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers with CYP2C19^☆35 and CYP2C19^☆2 Alleles
Chaudhry AS; Prasad B; Shirasaka Y; Fohner A; Finkelstein D; Fan Y; Wang S; Wu G; Aklillu E; Sim SC; Thummel KE; Schuetz EG
Article: OMICS A JOURNAL OF INTEGRATIVE BIOLOGY. 2015;19(6):346-353
Differences in CYP2C9 Genotype and Enzyme Activity Between Swedes and Koreans of Relevance for Personalized Medicine: Role of Ethnicity, Genotype, Smoking, Age, and Sex
Hatta FHM; Lundblad M; Ramsjo M; Kang J-H; Roh H-K; Bertilsson L; Eliasson E; Aklillu E
Article: MALARIA JOURNAL. 2015;14:179
The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment
Maganda BA; Ngaimisi E; Kamuhabwa AAR; Aklillu E; Minzi OMS
Article: PLOS ONE. 2015;10(5):e0122587
Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts < 200 Cells/μL: TB-HAART Study, a Randomized Clinical Trial
Amogne W; Aderaye G; Habtewold A; Yimer G; Makonnen E; Worku A; Sonnerborg A; Aklillu E; Lindquist L
Article: PHARMACOGENOMICS. 2015;16(10):1047-1064
Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study
Habtewold A; Makonnen E; Amogne W; Yimer G; Aderaye G; Bertilsson L; Burhenne J; Aklillu E
Article: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2014;69(12):3311-3319
Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment
Ngaimisi E; Minzi O; Mugusi S; Sasi P; Riedel K-D; Suda A; Ueda N; Bakari M; Janabi M; Mugusi F; Bertilsson L; Burhenne J; Aklillu E; Diczfalusy U
Article: PHARMACOGENETICS AND GENOMICS. 2014;24(8):409-425
PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2
McDonagh EM; Boukouvala S; Aklillu E; Hein DW; Altman RB; Klein TE
Article: PHARMACOGENOMICS. 2014;15(11):1423-1435
CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure
Mukonzo JK; Nanzigu S; Waako P; Ogwal-Okeng J; Gustafson LL; Aklillu E
Article: OMICS A JOURNAL OF INTEGRATIVE BIOLOGY. 2014;18(7):446-453
High CYP2A6 Enzyme Activity as Measured by a Caffeine Test and Unique Distribution of CYP2A6 Variant Alleles in Ethiopian Population
Aklillu E; Djordjevic N; Carrillo JA; Makonnen E; Bertilsson L; Ingelman-Sundberg M
Article: JOURNAL OF APPLIED GENETICS. 2014;55(2):163-171
The VKORC1 Asp36Tyr variant and VKORC1 haplotype diversity in Ashkenazi and Ethiopian populations
Sominsky S; Korostishevsky M; Kurnik D; Aklillu E; Cohen Y; Ken-Dror G; Loebstein R; Halkin H; Gak E
Article: LIVER INTERNATIONAL. 2014;34(3):367-378
Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts
Thulin P; Nordahl G; Gry M; Yimer G; Aklillu E; Makonnen E; Aderaye G; Lindquist L; Mattsson CM; Ekblom B; Antoine DJ; Park BK; Linder S; Harrill AH; Watkins PB; Glinghammar B; Schuppe-Koistinen I
Article: PLOS ONE. 2014;9(4):e94271
Evaluation of Patterns of Liver Toxicity in Patients on Antiretroviral and Anti-Tuberculosis Drugs: A Prospective Four Arm Observational Study in Ethiopian Patients
Yimer G; Gry M; Amogne W; Makonnen E; Habtewold A; Petros Z; Aderaye G; Schuppe-Koistinen I; Lindquist L; Aklillu E
Article: PLOS ONE. 2014;9(1):e86919
Pharmacogenetic-Based Efavirenz Dose Modification: Suggestions for an African Population and the Different CYP2B6 Genotypes
Mukonzo JK; Owen JS; Ogwal-Okeng J; Kuteesa RB; Nanzigu S; Sewankambo N; Thabane L; Gustafsson LL; Ross C; Aklillu E
Article: PHARMACOGENOMICS JOURNAL. 2013;13(6):484-489
Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients
Habtewold A; Amogne W; Makonnen E; Yimer G; Nylen H; Riedel K-D; Aderaye G; Bertilsson L; Burhenne J; Diczfalusy U; Aklillu E
Article: BMC INFECTIOUS DISEASES. 2013;13:536
CCL3L1 copy number, HIV load, and immune reconstitution in sub-Saharan Africans
Aklillu E; Odenthal-Hesse L; Bowdrey J; Habtewold A; Ngaimisi E; Yimer G; Amogne W; Mugusi S; Minzi O; Makonnen E; Janabi M; Mugusi F; Aderaye G; Hardwick R; Fu B; Viskaduraki M; Yang F; Hollox EJ
Article: BMC INFECTIOUS DISEASES. 2013;13:261
Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study
Mukonzo JK; Okwera A; Nakasujja N; Luzze H; Sebuwufu D; Ogwal-Okeng J; Waako P; Gustafsson LL; Aklillu E
Article: ENVIRONMENTAL AND MOLECULAR MUTAGENESIS. 2013;54(2):124-132
Haplotypes in the 5′-untranslated region of the CYP1A2gene are inversely associated with lung cancer risk but do not correlate with caffeine metabolism
Gervasini G; Ghotbi R; Aklillu E; San Jose C; Cabanillas A; Kishikawa J; Benitez J; Antonio Carrillo J
Article: DRUG METABOLISM AND PHARMACOKINETICS. 2013;28(2):93-97
Comparisons of CYP2A6 Genotype and Enzyme Activity between Swedes and Koreans
Djordjevic N; Antonio Carrillo J; van den Broek MPJ; Kishikawa J; Roh H-K; Bertilsson L; Aklillu E
Article: PLOS ONE. 2013;8(11):e78165
Copy Number Variation of Fc Gamma Receptor Genes in HIV-Infected and HIV-Tuberculosis Co-Infected Individuals in Sub-Saharan Africa
Machado LR; Bowdrey J; Ngaimisi E; Habtewold A; Minzi O; Makonnen E; Yimer G; Amogne W; Mugusi S; Janabi M; Aderaye G; Mugusi F; Viskaduraki M; Aklillu E; Hollox EJ
Article: PLOS ONE. 2013;8(7):e67946
Importance of Ethnicity, CYP2B6 and ABCB1 Genotype for Efavirenz Pharmacokinetics and Treatment Outcomes: A Parallel-Group Prospective Cohort Study in Two Sub-Saharan Africa Populations
Ngaimisi E; Habtewold A; Minzi O; Makonnen E; Mugusi S; Amogne W; Yimer G; Riedel K-D; Janabi M; Aderaye G; Mugusi F; Bertilsson L; Aklillu E; Burhenne J
Article: PHARMACOGENOMICS JOURNAL. 2012;12(6):499-506
High plasma efavirenz level and CYP2B6^*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naive HIV patients from Ethiopia: a prospective cohort study
Yimer G; Amogne W; Habtewold A; Makonnen E; Ueda N; Suda A; Worku A; Haefeli WE; Burhenne J; Aderaye G; Lindquist L; Aklillu E
Article: JOURNAL OF CLINICAL PHARMACOLOGY. 2012;52(10):1527-1534
Comparison of N-Acetyltransferase-2 Enzyme Genotype-Phenotype and Xanthine Oxidase Enzyme Activity Between Swedes and Koreans
Djordjevic N; Carrillo JA; Roh H-K; Karlsson S; Ueda N; Bertilsson L; Aklillu E
Article: JOURNAL OF INFECTIOUS DISEASES. 2012;206(7):1012-1019
β-defensin Genomic Copy Number Is Associated With HIV Load and Immune Reconstitution in Sub-Saharan Africans
Hardwick RJ; Amogne W; Mugusi S; Yimer G; Ngaimisi E; Habtewold A; Minzi O; Makonnen E; Janabi M; Machado LR; Viskaduraki M; Mugusi F; Aderaye G; Lindquist L; Hollox EJ; Aklillu E
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2012;68(7):1033-1042
Search for the molecular basis of ultra-rapid CYP2C9-catalysed metabolism: relationship between SNP IVS8-109A>T and the losartan metabolism phenotype in Swedes
Hatta FHM; Teh LK; Hellden A; Hellgren KE; Roh H-K; Salleh MZ; Aklillu E; Bertilsson L
Article: PHARMACOGENETICS AND GENOMICS. 2012;22(5):389-395
PharmGKB summary: caffeine pathway
Thorn CF; Aklillu E; McDonagh EM; Klein TE; Altman RB
Article: ANTIVIRAL THERAPY. 2012;17(2):265-274
Risk factors for mortality among HIV-positive patients with and without active tuberculosis in Dar es Salaam, Tanzania
Mugusi SF; Ngaimisi E; Janabi MY; Mugusi FM; Minzi OMS; Sasi PG; Bakari M; Lindquist L; Aklillu E; Sandstrom EG
Article: PHARMACOGENETICS AND GENOMICS. 2012;22(1):73-77
PharmGKB summary: very important pharmacogene information for CYP1A2
Thorn CF; Aklillu E; Klein TE; Altman RB
Article: PLOS ONE. 2012;7(7):e40180
Liver Enzyme Abnormalities and Associated Risk Factors in HIV Patients on Efavirenz-Based HAART with or without Tuberculosis Co-Infection in Tanzania
Mugusi S; Ngaimisi E; Janabi M; Minzi O; Bakari M; Riedel K-D; Burhenne J; Lindquist L; Mugusi F; Sandstrom E; Aklillu E
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2011;67(11):1139-1145
Frequency of the SLCO1B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler®-based method
Aklillu E; Mugusi S; Ngaimisi E; Hoffmann MM; Koenig S; Ziesenitz V; Mikus G; Haefeli WE; Weiss J
Article: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2011;66(10):2350-2361
Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients
Habtewold A; Amogne W; Makonnen E; Yimer G; Riedel K-D; Ueda N; Worku A; Haefeli WE; Lindquist L; Aderaye G; Burhenne J; Aklillu E
Journal article: CLINICAL PHARMACOKINETICS. 2011;50(9):624
Erratum to: HIV/AIDS patients display lower relative bioavailability of efavirenz than healthy subjects
Mukonzo JK; Nanzigu S; Rekić D; Waako P; Röshammar D; Ashto M; Ogwal-Okeng J; Gustafsson LL; Aklillu E
Article: CLINICAL PHARMACOLOGY AND THERAPEUTICS. 2011;90(3):406-413
Effect of Rifampicin and CYP2B6 Genotype on Long-Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis
Ngaimisi E; Mugusi S; Minzi O; Sasi P; Riedel K-D; Suda A; Ueda N; Janabi M; Mugusi F; Haefeli WE; Bertilsson L; Burhenne J; Aklillu E
Article: CLINICAL PHARMACOKINETICS. 2011;50(8):531-540
HIV/AIDS Patients Display Lower Relative Bioavailability of Efavirenz than Healthy Subjects
Mukonzo JK; Nanzigu S; Rekic D; Waako P; Roshammar D; Ashton M; Ogwal-Okeng J; Gustafsson LL; Aklillu E
Article: JOURNAL OF CLINICAL PHARMACOLOGY. 2011;51(7):994-1003
N-acetyltransferase-2 (NAT2) Gene Polymorphisms and Enzyme Activity in Serbs: Unprecedented High Prevalence of Rapid Acetylators in a White Population
Djordjevic N; Antonio Carrillo J; Ueda N; Gervasini G; Fukasawa T; Suda A; Jankovic S; Aklillu E
Article: PHARMACOGENOMICS JOURNAL. 2011;11(2):130-137
Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians
Gebeyehu E; Engidawork E; Bijnsdorp A; Aminy A; Diczfalusy U; Aklillu E
Article: PLOS ONE. 2011;6(12):e27810
Pharmacogenetic & Pharmacokinetic Biomarker for Efavirenz Based ARV and Rifampicin Based Anti-TB Drug Induced Liver Injury in TB-HIV Infected Patients
Yimer G; Ueda N; Habtewold A; Amogne W; Suda A; Riedel K-D; Burhenne J; Aderaye G; Lindquist L; Makonnen E; Aklillu E
Article: CLINICAL PHARMACOLOGY AND THERAPEUTICS. 2010;88(5):676-684
Long-Term Efavirenz Autoinduction and Its Effect on Plasma Exposure in HIV Patients
Ngaimisi E; Mugusi S; Minzi OM; Sasi P; Riedel K-D; Suda A; Ueda N; Janabi M; Mugusi F; Haefeli WE; Burhenne J; Aklillu E
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2010;66(9):871-877
CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking
Ramsjo M; Aklillu E; Bohman L; Ingelman-Sundberg M; Roh H-K; Bertilsson L
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2010;66(7):697-703
Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2-163C>A polymorphism
Djordjevic N; Ghotbi R; Jankovic S; Aklillu E
Article: THERAPEUTIC DRUG MONITORING. 2010;32(3):346-352
Genetic Variations in ABCB1 and CYP3A5 as well as Sex Influence Quinine Disposition Among Ugandans
Mukonzo JK; Waako P; Ogwal-Okeng J; Gustafsson LL; Aklillu E
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2010;66(6):571-578
In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population
Djordjevic N; Carrillo JA; Gervasini G; Jankovic S; Aklillu E
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2010;66(5):465-474
Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure-an impact similar to male gender or smoking in schizophrenic patients
Ghotbi R; Mannheimer B; Aklillu E; Suda A; Bertilsson L; Eliasson E; Osby U
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2009;68(5):690-699
A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans
Mukonzo JK; Roshammar D; Waako P; Andersson M; Fukasawa T; Milani L; Svensson JO; Ogwal-Okeng J; Gustafsson LL; Aklillu E
Article: PHARMACOGENOMICS JOURNAL. 2009;9(3):208-217
Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers
Ghotbi R; Gomez A; Milani L; Tybring G; Syvanen A-C; Bertilsson L; Ingelman-Sundberg M; Aklillu E
Article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2009;19(5):363-370
MAO-A and COMT genotypes as possible regulators of perinatal serotonergic symptoms after in utero exposure to SSRIs
Hilli J; Heikkinen T; Rontu R; Lehtimaki T; Kishida I; Aklillu E; Bertilsson L; Vahlberg T; Laine K
Article: PHARMACOGENETICS AND GENOMICS. 2009;19(4):267-275
Association of MAOA gene functional promoter polymorphism with CSF dopamine turnover and atypical depression
Aklillu E; Karlsson S; Zachrisson OO; Ozdemir V; Agren H
Article: HUMAN MUTATION. 2008;29(9):1147-1153
Mutations in CYP1B1 cause primary congenital glaucoma by reduction of either activity or abundance of the enzyme
Chavarria-Soley G; Sticht H; Aklillu E; Ingelman-Sundberg M; Pasutto F; Reis A; Rautenstrauss B
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2008;64(4):381-385
Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes
Djordjevic N; Ghotbi R; Bertilsson L; Jankovic S; Aklillu E
Article: PLOS ONE. 2008;3(3):e1809
Anti-Tuberculosis Therapy-Induced Hepatotoxicity among Ethiopian HIV-Positive and Negative Patients
Yimer G; Aderaye G; Amogne W; Makonnen E; Aklillu E; Lindquist L; Yamuah L; Feleke B; Aseffa A
Article: PHARMACOGENETICS AND GENOMICS. 2008;18(3):201-208
4β-Hydroxycholesterol is a new endogenous CYP3A marker:: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians
Diczfalusy U; Miura J; Roh H-K; Mirghani RA; Sayi J; Larsson H; Bodin KG; Allqvist A; Jande M; Kim J-W; Aklillu E; Gustafsson LL; Bertilsson L
Article: PHARMACOGENETICS AND GENOMICS. 2007;17(11):989-993
CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine
Aklillu E; Kalow W; Endrenyi L; Harper P; Miura J; Ozdemir V
Article: NEUROPSYCHOPHARMACOLOGY. 2007;32(10):2143-2151
Monoamine metabolites level in CSF is related to the 5-HTT gene polymorphism in treatment-resistant depression
Kishida I; Aklillu E; Kawanishi C; Bertilsson L; Agren H
Article: CLINICAL PHARMACOLOGY AND THERAPEUTICS. 2007;81(5):708-712
CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir
Josephson F; Allqvist A; Janabi M; Sayi J; Aklillu E; Jande M; Mahindi M; Burhenne J; Bottiger Y; Gustafsson LL; Haefeli WE; Bertilsson L
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2007;63(6):537-546
Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans
Ghotbi R; Christensen M; Roh H-K; Ingelman-Sundberg M; Aklillu E; Bertilsson L
Article: PHARMACOGENETICS AND GENOMICS. 2006;16(9):637-645
CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population
Mirghani RA; Sayi J; Aklillu E; Allqvist A; Jande M; Wennerholm A; Eriksen J; Herben VMM; Jones BC; Gustafsson LL; Bertilsson L
Article: PHARMACOGENETICS AND GENOMICS. 2006;16(5):359-367
Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype
Jiang Z; Dragin N; Jorge-Nebert LF; Martin MV; Guengerich FP; Aklillu E; Ingelman-Sundberg M; Hammons GJ; Lyn-Cook BD; Kadlubar FF; Saldana SN; Sorter M; Vinks AA; Nassr N; von Richter O; Jin L; Nebert DW
Article: CLINICAL PHARMACOLOGY AND THERAPEUTICS. 2006;79(1):103-113
A common novel CTP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants
Sim SC; Risinger C; Dahl ML; Aklillu E; Christensen M; Bertilsson L; Ingelman-Sundberg M
Article: CANCER RESEARCH. 2005;65(12):5105-5111
Characterization of common CYP1B1 variants with different capacity for benzo[a] pyrene-7,8-dihydrodiol epoxide formation from benzo[a]pyrene
Aklillu E; Ovrebo S; Botnen IV; Otter C; Ingelman-Sundberg M
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2003;59(7):533-536
Xanthine oxidase activity is influenced by environmental factors in Ethiopians
Aklillu E; Carrillo JA; Makonnen E; Bertilsson L; Ingelman-Sundberg M
Article: MOLECULAR PHARMACOLOGY. 2003;64(3):659-669
Genetic polymorphism of CYP1A2 in ethiopians affecting induction and expression: Characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1
Aklillu E; Carrillo JA; Makonnen E; Hellman K; Pitarque M; Bertilsson L; Ingelman-Sundberg M
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2002;58(8):555-558
Analysis of CYP2C9*5 in Caucasian, Oriental and black-African populations
Yasar Ü; Aklillu E; Canaparo R; Sandberg M; Sayi J; Roh HK; Wennerholm A
Journal article: DRUG NEWS AND PERSPECTIVES. 2002;15(8):528-534
Recent Progress in Drug Metabolism Research.
Aklillu E; Hidestrand M; Ingelman-Sundberg M; Malmebo S; Westlind A
Article: PHARMACOGENETICS AND GENOMICS. 2002;12(5):375-383
Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden
Aklillu E; Herrlin K; Gustafsson LL; Bertilsson L; Ingelman-Sundberg M
Article: MOLECULAR PHARMACOLOGY. 2002;61(3):586-594
Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population
Aklillu E; Oscarson M; Hidestrand M; Leidvik B; Otter C; Ingelman-Sundberg M
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2001;52(4):447-450
Genetic polymorphism of cytochrome P4502C9 in a Caucasian and a black African population
Scordo MG; Aklillu E; Yasar U; Dahl ML; Spina E; Ingelman-Sundberg M
Article: PHARMACOGENETICS AND GENOMICS. 1996;6(6):521-526
S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among ethiopians
Persson I; Aklillu E; Rodrigues F; Bertilsson L; IngelmanSundberg M
Article: JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. 1996;278(1):441-446
Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles
Aklillu E; Persson I; Bertilsson L; Johansson I; Rodrigues F; IngelmanSundberg M
Visa fler

Alla övriga publikationer

Letter: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2024;80(7):1111-1112
"Always look at the outliers": in memoriam Leif Bertilsson
Stingl J; Aklillu E; Masimirembwa C; Kek TL
Review: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2024;141:107002
Screening for latent tuberculosis in migrants-status quo and future challenges
Petersen E; Al-Abri S; Al-Jardani A; Memish ZA; Aklillu E; Ntoumi F; Mwaba P; Wejse C; Zumla A; Al-Yaquobi F
Conference publication: 2023;:a37.3-a3a38
PA-118 Safety monitoring during mass drug administration: adverse events following the use of Ivermectin, Diethylcarbamazine and Albendazole for the control of lymphatic filariasis in Kenya
Khaemba C; Barry A; Omondi W; Kirui E; Mandale M; Oluka M; Gurumurthy P; Njenga S; Guantai A; Aklillu E
Conference publication: 2023;:a35.2-a3a35
PA-96 Surveillance of hematological and biochemical changes following mass Ivermectin and Albendazole administration for the control of lymphatic filariasis in endemic communities of Tanzania
Fimbo AM; Minzi O; Aklillu E
Conference publication: 2023;:a32.1-a3a32
PA-74 Efficacy of single dose albendazole for the treatment of soil-transmitted infections among school children in Southern Ethiopia
Gebreyesus TD; Makonnen E; Tadele T; Mekete K; Gashaw H; Gerba H; Aklillu E
Editorial comment: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2023;131:180-182
End of the Bedaquiline patent - a crucial development for moving forward affordable drugs, diagnostics, and vaccines for infectious diseases in low- and middle-income countries
Petersen E; Hui DS; Nachega JB; Ntoumi F; Goletti D; Aklillu E; Sharma A; Nyirenda T; Yeboah-Manu D; Satta G; da Costa C; Azhar EI; Bockarie M; Al-Abri S; Mchugh TD; Rodriguez-Morales AJ; Varghese G; Zumla A
Editorial comment: THE LANCET RESPIRATORY MEDICINE. 2022;10(6):533-536
Optimising tuberculosis care for refugees affected by armed conflicts Comment
Castro KG; Ditiu L; Sahu S; Ntoumi F; Tiberi S; O'Kane CM; Akkerman O; Manika K; Mwaba P; Forsman LD; Petersen E; Aklillu E; Azhar EI; Cirillo DM; Migliori G-B; Abbara A; Zumla A
Editorial comment: THE LANCET INFECTIOUS DISEASES. 2022;22(4):442-444
World Tuberculosis Day 2022: aligning COVID-19 and tuberculosis innovations to save lives and to end tuberculosis
Ntoumi F; Nachega JB; Aklillu E; Chakaya J; Felker I; Amanullah F; Yeboah-Manu D; Castro KG; Zumla A
Editorial comment: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2022;114:268-272
Emergence of new SARS-CoV-2 Variant of Concern Omicron (B.1.1.529)-highlights Africa's research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts
Petersen E; Ntoumi F; Hui D; Abubakar A; Kramer LD; Obiero C; Tambyah PA; Blumberg L; Yapi R; Al-Abri S; Pinto TDCA; Yeboah-Manu D; Haider N; Asogun D; Velavan TP; Kapata N; Bates M; Ansumana R; Montaldo C; Mucheleng'anga L; Tembo J; Mwaba P; Himwaze C; Hamid MMA; Mfinanga S; Mboera L; Raj T; Aklillu E; Veas F; Edwards S; Kaleebu P; McHugh TD; Chakaya J; Nyirenda T; Bockarie M; Nyasulu PS; Wejse C; Muyembe-Tamfum J-J; Azhar EI; Maeurer M; Nachega JB; Kock R; Ippolito G; Zumla A
Review: PHARMACOGENOMICS AND PERSONALIZED MEDICINE. 2022;15:561-571
Effect of Genetic Variations in Drug-Metabolizing Enzymes and Drug Transporters on the Pharmacokinetics of Rifamycins: A Systematic Review
Sileshi T; Mekonen G; Makonnen E; Aklillu E
Review: EXPERT OPINION ON DRUG METABOLISM AND TOXICOLOGY. 2021;17(9):1125-1138
The impact of catha edulis (vahl) forssk. ex endl. (celestraceae) (khat) on pharmacokinetics of clinically used drugs
Aklillu E; Engidawork E
Preprint: RESEARCH SQUARE. 2020
Effect of Sulfadoxine-Pyrimethamine doses for prevention of malaria during pregnancy in hypoendemic area in Tanzania
Mikomangwa WP; Minzi O; Mutagonda R; Baraka V; Mlugu E; Aklillu E; Kamuhabwa AAR
Preprint: RESEARCH SQUARE. 2019
Effect of Sulfadoxine-Pyrimethamine doses for prevention of malaria during pregnancy in hypoendemic area in Tanzania
Mikomangwa WP; Minzi O; Mutagonda R; Baraka V; Mlugu EM; Aklillu E; Kamuhabwa AAR
Letter: HIV MEDICINE. 2019;20(7):e13-e14
Rebuttal: Response to the comments by Buck et al. on our published article: Hepatic and renal toxicity and associated factors among HIV-infected children on antiretroviral therapy: a prospective cohort study; HIV Medicine (2019), 20, 147-156
Tadesse BT; Foster A; Aklillu E
Review: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2019;85(3):467-475
Conference report: pharmacogenomics in special populations at WCP2018
Suarez-Kurtz G; Aklillu E; Saito Y; Somogyi AA
Conference publication: TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE. 2019;113:S270-S271
HIV AND CART ASSOCIATED DYSLIPIDEMIA AMONG HIV INFECTED CHILDREN
Tadesse BT; Foster BA; Bizuayehu T; Ayalew F; Meskel GH; Jerene D; Makonnen E; Aklillu E
Conference publication: HIV MEDICINE. 2019;20:285
Rifampicin pharmacokinetics and pharmacogenetics in Ugandan patients with multi-drug resistant tuberculosis
Mukonzo JK; Kengo A; Kutesa R; Nanzigu S; Pohanka A; Hugh M; Zumla A; Aklillu E
Preprint: AAS OPEN RES. 2019
African Pharmacogenomics Consortium: Consolidating pharmacogenomics knowledge, capacity development and translation in Africa
Dandara C; Masimirembwa C; Haffani Y; Ogutu B; Mabuka J; Aklillu E; Bolaji O; H3Africa
Conference publication: DRUG SAFETY. 2018;41(11):1107-1108
The Proforma Project Presentation
Aklillu E
Conference publication: JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 2018;21:122
Efavirenz plasma exposure and immunologic outcome during anti-tuberculosis co-therapy: role of ethnicity and pharmacogenetic variations
Mugusi S; Amogne W; Habtewold A; Ngaimisi E; Yimer G; Minzi O; Makonnene E; Mugusi F; Sudfeld C; Janabi M; Burhenne J; Aklillu E
Review: OMICS A JOURNAL OF INTEGRATIVE BIOLOGY. 2017;21(3):123-131
Genome-Wide Association Studies for Idiosyncratic Drug-Induced Hepatotoxicity: Looking Back-Looking Forward to Next-Generation Innovation
Petros Z; Makonnen E; Aklillu E
Conference publication: CLINICAL PHARMACOLOGY AND THERAPEUTICS. 2017;101(S1):S66-S67
POPULATION PHARMACOKINETICS OF A MAJOR METABOLITE OF EFAVIRENZ, 8-HYDROXY-EFAVIRENZ, IN PLASMA AND PERIPHERAL BLOOD MONONUCLEAR CELLS
Habtewold A; Aklillu E; Makonnen E; Yimer G; Bertilsson L; Burhenne J; Owen J
Editorial comment: OMICS A JOURNAL OF INTEGRATIVE BIOLOGY. 2016;20(9):493-495
Precision Medicine 2.0: The Rise of Glocal Innovation, Superconnectors, and Design Thinking
Dandara C; Endrenyi L; Kolker E; Hekim N; Steuten LMG; Gungor K; Aklillu E; Ozdemir V
Letter: OMICS A JOURNAL OF INTEGRATIVE BIOLOGY. 2016;20(4):259-262
An Open Letter in Support of Transformative Biotechnology and Social Innovation: SANKO University Innovation Summit in Medicine and Integrative Biology, Gaziantep, Turkey, May 5-7, 2016
Saygili EI; Abou-Zeid AH; Akkin SM; Aklillu E; Barlas IO; Borda-Rodriguez A; Boschele FA; Cetin Z; Coskun E; Coskun Y; Dagli G; Dai TU; Dandara C; Dereli T; Elbeyli L; Endrenyi L; Eyigun CP; Georgakilas A; Gunbulut B; Gungor K; Guzelbey A; Hekim C; Huzair F; Kimyon S; Karakas U; Lin B; LLerena A; Masimirembwa C; McNally R; Mete A; Sancar P; Srivastava S; Steuten LM; Tanriover O; Tyfield D; Tore VI; Vuruskan D; Wang W; Warnich L; Wonkam A; Yildirim YZ; Yilmaz I; Sinav A; Hekim N
Editorial comment: CLINICAL INFECTIOUS DISEASES. 2015;61(9):1432-1438
Host-Directed Therapies for Tackling Multi-Drug Resistant Tuberculosis: Learning From the Pasteur-Bechamp Debates
Zumla A; Maeurer M; Chakaya J; Hoelscher M; Ntoumi F; Rustomjee R; Vilaplana C; Yeboah-Manu D; Rasolofo V; Munderi P; Singh N; Aklillu E; Padayatchi N; Macete E; Kapata N; Mulenga M; Kibiki G; Mfinanga S; Nyirenda T; Mboko L; Garcia-Basteiro AL; Rakotosamimanana N; Bates M; Mwaba P; Reither K; Gagneux S; Edwards S; Mfinanga E; Abdulla S; Cardona P-J; Russell JBW; Gant V; Noursadeghi M; Elkington P; Bonnet M; Menendez C; Dieye TN; Diarra B; Maiga A; Aseffa A; Parida S; Wejse C; Petersen E; Kaleebu P; Oliver M; Craig G; Corrah T; Tientcheu L; Antonio M; McHugh TD; Sheikh A; Ippolito G; Ramjee G; Kaufmann SHE; Churchyard G; Steyn AJC; Grobusch MP; Sanne I; Martinson N; Mandansein R; Wilkinson RJ; Wallis RS; Mayosi B; Schito M
Editorial comment: NATURE REVIEWS DRUG DISCOVERY. 2015;14(8):511-512
Towards host-directed therapies for tuberculosis
Zumla A; Maeurer M; Chakaya J; Hoelscher M; Ntoumi F; Rustomjee R; Vilaplana C; Yeboah-Manu D; Rasolofo V; Munderi P; Singh N; Aklillu E; Padayatchi N; Macete E; Kapata N; Mulenga M; Kibiki G; Mfinanga S; Nyirenda T; Maboko L; Garcia-Basteiro A; Rakotosamimanana N; Bates M; Mwaba P; Reither K; Gagneux S; Edwards S; Mfinanga E; Abdulla S; Cardona P-J; Russell JBW; Gant V; Noursadeghi M; Elkington P; Bonnet M; Menendez C; Dieye TN; Diarra B; Maiga A; Aseffa A; Parida S; Wejse C; Petersen E; Kaleebu P; Oliver M; Craig G; Corrah T; Tientcheu L; Antonio M; Rao M; McHugh TD; Sheikh A; Ippolito G; Ramjee G; Kaufmann SHE; Churchyard G; Steyn A; Grobusch M; Sanne I; Martinson N; Madansein R; Wilkinson RJ; Mayosi B; Schito M; Wallis RS
Conference publication: JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS. 2015;42:S25
Pharmacogenetic-Based Pharmacokinetic Modeling of Plasma and Intracellular Concentrations of Efavirenz on Adult Ethiopian HIV and TB/HIV Patients
Habtewold A; Aklillu E; Makonnen E; Amogne W; Yimer G; Aderaye G; Bertilsson L; Burhenne J; Owen JS
Editorial comment: THE LANCET INFECTIOUS DISEASES. 2015;15(1):11-13
Genesis of EDCTP2
Zumla A; Makanga M; Nyirenda T; Beattie P; Olesen OF; Breugelmans JG; Aklillu E; Corrah T; Mgone C
Conference publication: BASIC AND CLINICAL PHARMACOLOGY AND TOXICOLOGY. 2014;115:232-233
TB-HIV CO-INFECTION AND CONCOMITANT ANTI-TB THERAPY AND HAART INCREASES THE RISK FOR DRUG INDUCED LIVER INJURY: A PROSPECTIVE FOUR-ARM COHORT STUDY
Ali G; Gry M; Amogne W; Makonnen E; Habtewold A; Petros Z; Aderaye G; Schuppe-Koistinen I; Lindquist L; Aklillu E
Conference publication: BASIC AND CLINICAL PHARMACOLOGY AND TOXICOLOGY. 2014;115:166
INVESTIGATING THE DETERMINANTS OF EFAVIRENZ PHARMACOKINETIC PARAMETERS AFTER LONG TERM TREATMENT WITH AND WITHOUT RIFAMPICIN AMONG TANZANIAN HIV/TB AND HIV PATIENTS
Ngaimisi E; Minzi O; Mugusi S; Janabi M; Sasi P; Mugusi F; Bertilsson L; Aklillu E; Burhenne J
Conference publication: BASIC AND CLINICAL PHARMACOLOGY AND TOXICOLOGY. 2014;115:73
IS THERE A NEED FOR EFAVIRENZ DOSAGE ADJUSTMENT DURING CONCOMITANT RIFAMPICIN BASED ANTITUBERCULOSIS THERAPY? FINDINGS FROM THE HIV-TB PHARMAGENE STUDY
Habtewold A; Makonnen E; Amogne W; Ali G; Aderaye G; Bertilsson L; Burhenne J; Aklillu E
Conference publication: TOXICOLOGY LETTERS. 2012;211:S48
Qualification of new biomarkers for drug-induced liver injury in a human cohort
Thulin P; Gry M; Nordahl G; Yimer G; Linder S; Aklillu E; Glinghammar B; Schuppe-Koistinen I
Conference publication: TOXICOLOGY LETTERS. 2012;211:S9
Pharmacogenomic biomarkers for drug induced liver injury
Aklillu E
Conference publication: TROPICAL MEDICINE AND INTERNATIONAL HEALTH. 2012;17:22-23
Optimization of TB and HIV co-treatment: pharmacokinetic and pharmacogenetic aspects of interaction between rifampicin and efavirenz (EFV)
Aklillu E
Conference publication: IMMUNOLOGY. 2011;135:141
β-Defensin genomic copy number is associated with HIV viral load and immune reconstitution in sub-Saharan Africans
Hardwick R; Amogne W; Mugusi S; Yimer G; Ngaimisi E; Habtewold A; Minzi O; Makonnen E; Janabi M; Machado L; Mugusi F; Aderaye G; Lindquist L; Hollox E; Aklillu E
Corrigendum: CLINICAL PHARMACOKINETICS. 2011;50(9):624
HIV/AIDS patients display lower relative bioavailability of efavirenz than healthy subjects (vol 50, pg 531, 2011)
Mukonzo JK; Nanzigu S; Rekic D; Waako P; Roeshammar D; Ashton M; Ogwal-Okeng J; Gustafsson LL; Aklillu E
Conference publication: BASIC AND CLINICAL PHARMACOLOGY AND TOXICOLOGY. 2011;109:23
XANTHINE OXIDASE AND N-ACETYLTRANSFERASE-2 ENZYME ACTIVITIES IN SWEDES AND KOREANS: AN INTER-ETHNIC COMPARISON
Djordjevic N; Carrillo JA; Gervasini G; Ueda N; Roh H-K; Aklillu E
Conference publication: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2009;68:7
THE AUTO INDUCTION OF EFAVIRENZ METABOLISM AND THE RESULTING EFFECT ON THE EFAVIRENZ STEADY STATE LEVELS IN TANZANIAN PATIENTS
Ngaimisi E; Mugusi S; Minzi O; Sasi P; Janabi M; Mugusi F; Bakari M; Aris E; Sandstrom E; Bertilsson L; Burhenne J; Aklillu E
Conference publication: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2009;68:6
STEADY STATE EFAVIRENZ PHARMACOKINETICS PROFILE AMONG HIV PATIENTS IN ETHIOPIA
Eyakem A; Amogne W; Yimer G; Makonnen E; Aderaye G; Bertilsson L; Burhenne J; Aklillu E
Conference publication: BASIC AND CLINICAL PHARMACOLOGY AND TOXICOLOGY. 2009;105:81
N-ACETYLTRANSFERASE-2 (NAT2) GENE POLYMORPHISMS AND ENZYME ACTIVITY IN SERBS: UNPRECEDENTED HIGH PREVALENCE OF RAPID ACETYLATORS IN A WHITE POPULATION
Djordjevic N; Carrillo JA; Gervasini G; Jankovic S; Aklillu E
Conference publication: BASIC AND CLINICAL PHARMACOLOGY AND TOXICOLOGY. 2009;105:21-22
CORRELATION OF CYP2A6 ENZYME ACTIVITY WITH GENOTYPE AND CIGARETTE SMOKING IN SERBS
Djordjevic N; Carrillo JA; Gervasini G; Jankovic S; Aklillu E
Letter: BLOOD. 2008;111(7):3903-3904
VKORC1 Asp36Tyr warfarin resistance marker is common in Ethiopian individuals
Aklillu E; Leong C; Loebstein R; Halkin H; Gak E
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2007;17:S328
Monoamine metabolites level in CSF are related to the 5-HTT gene polymorphism in treatment-resistant depression
Kishida I; Aklillu E; Kawanishi C; Bertilsson L; Agren H
Meeting abstract: TOXICOLOGY LETTERS. 2006;164:S98
Distribution and concordance of phenotypically and genotypically determined acetylation status on patients taking anti-tuberculosis drugs in Ethiopia
Yimer G; Golka K; Aseffa A; Aklillu E; Makonnen E; Amogne W; Bobosha K; Rane A; LindquiSt L; Aderaye G
Meeting abstract: TOXICOLOGY LETTERS. 2006;164:S92
Anti-tubercular drug-induced hepatotoxicity in HIV-positive and negative patients
Yimer G; Aseffa A; Aklillu E; Makonnen E; Amogne W; Bobosha K; Golka K; Rane A; Lindquist L; Aderaye G
Meeting abstract: INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY. 2006;21(4):A33
CYP3A4 and 3A5 catalysed alprazolam metabolism in vitro and in vivo
Miura J; Aklillu E; Allqvist A; Gustafsson LL; Jande M; Mirghani RA; Sayi J; Wennerholm A; Widen J; Bertilsson L
Review: EXPERT OPINION ON PHARMACOTHERAPY. 2006;7(2):119-133
Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines
Ozdemir V; Aklillu E; Mee S; Bertilsson L; Albers LJ; Graham JE; Caligiuri M; Lohr JB; Reist C
Conference publication: NORDIC JOURNAL OF PSYCHIATRY. 2005;59(5):413
Monoamine metabolites in CSF are related to serotonin transporter promoter gene polymorphism in treatment-resistant major depression.
Kishida I; Aklillu E; Bertilsson L; Ågren H; Kawanishi C
Conference publication: CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY. 2004;31(11):A220
Genetic polymorphisms of CYP1A2 and xanthine oxidase in ethiopians affecting expression: Characterization of novel CYP1A2 haplotypes
Aklillu E; Carrillo JA; Mekonen E; Bertilsson L; Ingelman-Sundberg M
Thesis / dissertation: 2003
Pharmacogenetics of drug metabolizing enzymes with special emphasis on Ethiopians
Aklillu, Eleni
Visa fler

Forskningsbidrag

Building resilient research ethics, Diagnostics and medicines regulatory capacity during routine and public health emergency periods (BREEDIME)
Global Health EDCTP3 Joint Undertaking
1 June 2024 - 31 May 2026
Safety and efficacy of Dolutegravir and EFV400 for pregnant and breast feeding women: a randomized non-inferiority clinical trial (PREGART)
EDCTP
1 June 2018 - 31 December 2025
Pharmacovigilance infrastructure and post-marketing surveillance system capacity building for regional medicine regulatory harmonization in East Africa
European & Developing Countries Clinical Trials Partnership
1 March 2018 - 31 August 2024
Randomized clinical trial to identify optimal pediatric efavirenz dosage to treat HIV infected infant and children in Africa
Swedish Research Council
1 January 2016 - 31 December 2019
Healthcare associated infections, antimicrobial use and resistance in Ethiopia: an intervention study for rational antimicrobials use, prevention of resistance and limit their spread.
Swedish Research Council
1 January 2012 - 31 December 2014
Vårdrelaterade infektioner, antimikrobiella användningen och multiresistenta bakterier-en interventionsstudie för rationell antibiotika användning, förebyggande av infektion utbrott
Swedish Research Council
1 January 2012 - 31 December 2014
Metabolism, transport and effects of drugs - Pharmacogenetic, interethnic, and clinical aspects
Swedish Research Council
1 January 2010 - 31 December 2012

Anställningar

Professor, Global folkhälsa, Karolinska Institutet, 2023-

Examina och utbildning

Docent, Farmakologi, Karolinska Institutet, 2009
MEDICINE DOKTORSEXAMEN, Institutet för miljömedicin, Karolinska Institutet, 2003

Uppdrag

Forskargruppsledare, Global Health Pharmacology and Therapeutics (GH-Pharma) – Eleni Aklillu's research group, Department of Global Public Health, Karolinska Institutet, 2023-

Handledare

Joseph Kabatende, Pharmacovigilance of mass drug administration for the control of schistosomiasis and soil transmitted helminths in Rwanda., https://openarchive.ki.se/xmlui/handle/10616/48601

Artiklar

Alla övriga publikationer

Forskningsbidrag

Anställningar

Examina och utbildning

Uppdrag

Handledare

Nyheter från KI

Kalenderhändelser från KI